CRON
Price
$2.71
Change
-$0.23 (-7.82%)
Updated
May 1, 6:59 PM EST
7 days until earnings call
TAK
Price
$13.19
Change
+$0.10 (+0.76%)
Updated
May 1, 6:59 PM EST
7 days until earnings call
Ad is loading...

Analysis and predictions CRON vs TAK

Header iconCRON vs TAK Comparison
Open Charts CRON vs TAKBanner chart's image
Cronos Group
Price$2.71
Change-$0.23 (-7.82%)
Volume$3.55M
CapitalizationN/A
Takeda Pharmaceutical
Price$13.19
Change+$0.10 (+0.76%)
Volume$463.58K
CapitalizationN/A
View a ticker or compare two or three
CRON vs TAK Comparison Chart

Loading...

CRONDaily Signal changed days agoGain/Loss if shorted
 
Show more...
TAKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CRON vs. TAK commentary
May 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRON is a StrongSell and TAK is a Hold.

COMPARISON
Comparison
May 02, 2024
Stock price -- (CRON: $2.71 vs. TAK: $13.19)
Brand notoriety: CRON and TAK are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CRON: 186% vs. TAK: 81%
Market capitalization -- CRON: $1B vs. TAK: $43.11B
CRON [@Pharmaceuticals: Other] is valued at $1B. TAK’s [@Pharmaceuticals: Other] market capitalization is $43.11B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRON’s FA Score shows that 1 FA rating(s) are green whileTAK’s FA Score has 2 green FA rating(s).

  • CRON’s FA Score: 1 green, 4 red.
  • TAK’s FA Score: 2 green, 3 red.
According to our system of comparison, both CRON and TAK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRON’s TA Score shows that 4 TA indicator(s) are bullish while TAK’s TA Score has 6 bullish TA indicator(s).

  • CRON’s TA Score: 4 bullish, 4 bearish.
  • TAK’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, TAK is a better buy in the short-term than CRON.

Price Growth

CRON (@Pharmaceuticals: Other) experienced а +9.27% price change this week, while TAK (@Pharmaceuticals: Other) price change was -0.30% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.82%. For the same industry, the average monthly price growth was +30.06%, and the average quarterly price growth was +18979.84%.

Reported Earning Dates

CRON is expected to report earnings on Aug 08, 2024.

TAK is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+3.82% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for CRON with price predictions.
OPEN
A.I.dvisor published
a Summary for TAK with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
TAK($43.1B) has a higher market cap than CRON($1.01B). CRON YTD gains are higher at: 29.665 vs. TAK (-7.568). TAK has higher annual earnings (EBITDA): 1.01T vs. CRON (-71.8M). TAK has more cash in the bank: 317B vs. CRON (862M). CRON has less debt than TAK: CRON (2.55M) vs TAK (4.66T). TAK has higher revenues than CRON: TAK (4.17T) vs CRON (87.2M).
CRONTAKCRON / TAK
Capitalization1.01B43.1B2%
EBITDA-71.8M1.01T-0%
Gain YTD29.665-7.568-392%
P/E RatioN/A36.79-
Revenue87.2M4.17T0%
Total Cash862M317B0%
Total Debt2.55M4.66T0%
FUNDAMENTALS RATINGS
CRON vs TAK: Fundamental Ratings
CRON
TAK
OUTLOOK RATING
1..100
6111
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
9
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9287
PRICE GROWTH RATING
1..100
3775
P/E GROWTH RATING
1..100
125
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRON (72) in the Pharmaceuticals Other industry. This means that TAK’s stock grew somewhat faster than CRON’s over the last 12 months.

TAK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that TAK’s stock grew similarly to CRON’s over the last 12 months.

TAK's SMR Rating (87) in the Pharmaceuticals Major industry is in the same range as CRON (92) in the Pharmaceuticals Other industry. This means that TAK’s stock grew similarly to CRON’s over the last 12 months.

CRON's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for TAK (75) in the Pharmaceuticals Major industry. This means that CRON’s stock grew somewhat faster than TAK’s over the last 12 months.

CRON's P/E Growth Rating (1) in the Pharmaceuticals Other industry is in the same range as TAK (25) in the Pharmaceuticals Major industry. This means that CRON’s stock grew similarly to TAK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRONTAK
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
46%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
39%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
38%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
51%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
50%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
44%
Advances
ODDS (%)
Bullish Trend 6 days ago
75%
Bullish Trend 9 days ago
43%
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
Bearish Trend 6 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
53%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
35%
View a ticker or compare two or three
Ad is loading...
CRONDaily Signal changed days agoGain/Loss if shorted
 
Show more...
TAKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UNWPX1.510.01
+0.67%
US Global Investors World Prec Mnral
DTLGX38.31-0.06
-0.16%
Wilshire Large Company Growth Invmt
TIBAX24.50-0.07
-0.28%
Thornburg Investment Income Builder A
AMTKX8.69-0.05
-0.57%
AB All Market Real Return K
SAMVX11.94-0.09
-0.75%
Virtus Ceredex Mid-Cap Value Equity A

TAK and

Correlation & Price change

A.I.dvisor tells us that TAK and SNOA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TAK and SNOA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TAK
1D Price
Change %
TAK100%
+0.84%
SNOA - TAK
33%
Poorly correlated
-3.59%
OGI - TAK
29%
Poorly correlated
-9.67%
RDY - TAK
28%
Poorly correlated
+0.69%
CRON - TAK
26%
Poorly correlated
-7.82%
ELAN - TAK
26%
Poorly correlated
-0.08%
More